Use of ampicilin plus ranitidine for Helicobacter pylori gastritis
Braz. j. med. biol. res
;
24(6): 567-72, 1991. tab
Article
Dans Anglais
| LILACS
| ID: lil-99490
RESUMO
Helicobacter pylori (formerly Campylobacter pylori) is now recognized as an etiological factor in gastritis and duodenal ulcers and probably also gastric ulcers. Eradication of the bacteria is fundamental to avoid ulcer relapse. Although bismuth salts have been shown to be effective for treatment, they are not commercially available in Brazil. We report an attempt to treat patients with Helicobacter pylori-associated gastritis with ampicilin (1000 mg twice daily for one month) and compare the results with the conventional treatment used in Brazil (ranitidine, 300 mg daily for one month) and with a combination of the two drugs. We studied 44 patients with histologically confirmed gastritis and with Helicobacter pylori, who were examined at the beginning and after one month of treatment. Ampicilin associated with ranitidine was better than ampicilin or ranitidine alone for the treatment of gastritis. Although ampicilin may be more efficient in patients with lower acid output we did not find a statistically significant difference between these two groups (ampicilin vs drug combination), perhaps owing to the small number of patients studied. When ampicilin was with ranitidine there was 25% normalization of the histological picture of the gastric mucosa. We conclude that ampicilin in combination with ranitidine may be a useful treatment for Helicobacter pylori-associated gastritis
Recherche sur Google
Indice:
LILAS (Amériques)
Sujet Principal:
Ranitidine
/
Helicobacter pylori
/
Infections à Helicobacter
/
Gastrite
/
Ampicilline
Type d'étude:
Etude d'étiologie
Limites du sujet:
Humains
langue:
Anglais
Texte intégral:
Braz. j. med. biol. res
Thème du journal:
Biologie
/
Médicament
Année:
1991
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS